Dexmedetomidine Neuroprotection in Rat Cerebral Ischemia Models

A 17.4 MB dataset from a 2026 study by Xue Lv investigates dexmedetomidine's mechanism in alleviating blood-brain barrier disruption following cerebral ischemia-reperfusion injury in rats. The research combines network pharmacology predictions with in vivo validation using a rat model established via the suture-occlusion method. It includes results from neurological scoring, behavioral assessments, histological examination, western blotting, and immunofluorescence analysis.

Use Cases

• Validate network pharmacology predictions, like DEX targeting the AMPK/mTOR pathway, against in vivo protein expression data for P-AMPK/AMPK and P-mTOR/mTOR ratios.
• Correlate neurological scoring and behavioral assessment results with protein levels of tight junction markers like ZO-1 to model functional recovery.
• Analyze western blot and immunofluorescence data for autophagy markers beclin 1, LC3 II/I, and P62 to study their role in the observed neuroprotective effect.

Strengths

• Data integrates computational network pharmacology with multiple experimental validation methods, including western blot and immunofluorescence.
• Dataset is openly licensed under CC-BY-4.0, facilitating reuse and sharing.

Limitations

• The 17.4 MB size suggests a limited scope, potentially containing only summary-level results rather than raw individual animal data.
• Data is derived exclusively from a rat model, limiting direct translatability to human physiology.
• Specific sample sizes (number of animals, replicates) and raw data rows are not provided in the description.

Provenance

Source

Xue Lv via figshare.

Collection Method

Combination of network pharmacology analysis and in vivo experiments on a rat cerebral ischemia-reperfusion injury model, including neurological scoring, histology, western blot, and immunofluorescence.

Time Range

null

Freshness

Last updated in April 2026, indicating recent data.

Geography

null